Brain tumor drug trial seeks biomarkers to personalize treatment

NCT ID NCT06069726

First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 28 times

Summary

This study tests the drug atezolizumab in 80 adults whose glioblastoma has returned after standard treatment. The goal is to see if the drug helps people live longer and to find biological markers that predict who benefits most. Participants receive the drug before surgery, and researchers track survival and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Duke University

    RECRUITING

    Durham, North Carolina, 27705, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Huntsman Cancer Institute

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Saint Luke's Cancer Institute

    ACTIVE_NOT_RECRUITING

    Kansas City, Missouri, 64111, United States

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.